Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03301298 · ClinicalTrials.gov registry record · Phase 1
Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers
A Phase 1 study, sponsored by Promentis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT03301298 is a Phase 1 study that has completed, run by Promentis Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT03301298, a Phase 1 study, has completed, sponsored by Promentis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, single ascending oral dose and food effect study conducted at one study center in the United States. Safety and tolerability will be assessed throughout the study and serial blood samples and urine samples will be collected for the safety and pharmacokinetic assessment of SXC-2023.
Interventions
- DRUG Placebo oral capsule
- DRUG SXC-2023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-09-11 |
| Est. Completion | 2018-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03301298
The ClinicalTrials.gov registry entry for NCT03301298 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Promentis Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03301298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03301298 about?
NCT03301298 is a clinical study titled "Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers". This is a randomized, double-blind, placebo-controlled, single ascending oral dose and food effect study conducted at one study center in the United States. Safety and tolerability will be assessed throughout the study and serial blood samples and urine samples will be collected for the safety and p...
What is the current status of trial NCT03301298?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2017-09-11. Estimated completion is 2018-02-13.
What interventions are being tested in trial NCT03301298?
The interventions under investigation include: Placebo oral capsule (DRUG), SXC-2023 (DRUG).
Who is sponsoring clinical trial NCT03301298?
This trial is sponsored by Promentis Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.